Today oral steroid, about as popular as ever. In spite of what we know of their potential toxicity. C-17 alkylated agents such as methandrostenolone (Dianibol-Dbol), stanozolol (Winstrol) and oxymethonolone (Anadrol) remain staples on the underground steroid market.
Most users know the risk of liver injury is there, but also feel it to be exceedingly unlikely to happen to them. A paper published in the journal Substance Use & Misuse suggests that actual liver injury may be a bit more common in anabolic steroid users than typically assumed.
The paper discusses a study of 182 young steroid users from Brazil. The subjects lived freely, but ere monitored periodically over a period of roughly five years. Each of the men had used steroids for at least six months at the start of the study. What they found over the half decade period was a surprisingly high incidence of liver injury. A total of 38.8% had elevated liver enzymes. This, of course, is common in steroid users. Often ignored as not a big deal. Perhaps. However about 12% of the men suffered from hepatic steatosis, also known as fatty liver disease.
Even when excluding those men with a history of alcohol or other drug consumption, and existing liver disease, liver injury remained diagnosed in 12.6% of the steroid users (about 1 in 8 men). This does suggest that clinically significant issues could be more common than we assume. While the liver is indeed a resilient organ in most cases, it is still subject to injury from anabolic-androgenic steroids (AAS) misuse, as this study show.